Millions of individuals in the UK who rely on tricyclic medications to manage chronic pain are now confronting a difficult decision, as emerging evidence suggests these drugs may significantly increase the risk of developing dementia.
Nortriptyline, a type of tricyclic antidepressant originally developed for depression, is now a common treatment for various chronic pain conditions, including nerve pain, inflammatory bowel disease, and migraines. More than 2.5 million people in the UK take such medications. For many, these pills have been a crucial tool in regaining quality of life, enabling them to manage pain that affects approximately one in three adults and nearly half of those over 65.
However, recent studies have raised concerns. Research published in JAMA Internal Medicine in 2019 analyzed the health records of approximately 300,000 patients and concluded that those taking tricyclics were 50% more likely to develop dementia. Another study in The Lancet last year indicated that these drugs are associated with a notable increase in weight and heart rate, as well as a slight rise in blood pressure, all of which are risk factors for heart disease.
For individuals like Ethan Ennals, a health journalist who has been taking nortriptyline for two years to manage chronic back and hip pain stemming from axial spondyloarthritis, the news presents a significant dilemma. His GP recently advised him to stop the medication due to the potential dementia link. Yet, discontinuing the drug could lead to a return of debilitating pain, severely impacting his quality of life. Some experts even suggest that living with untreated chronic pain might, in itself, carry a risk for dementia, as pain can lead to reduced exercise and social interaction, both factors linked to lower dementia risk.
The exact mechanisms by which tricyclics might influence dementia risk are not fully understood. While they block certain nerve signals that can reduce pain, there is growing concern about potential long-term effects on the brain. Professor Ian Maidment, a clinical pharmacy expert at Aston University, notes that studies have primarily observed the effects in older patients, some of whom already had cognitive issues. Side effects like fatigue and confusion reported by patients on these drugs could potentially exacerbate or unmask pre-existing cognitive problems. However, he emphasizes that there is a lack of research on the long-term effects in younger individuals and no definitive data showing that stopping these medications reduces dementia risk.
Alternative pain management strategies exist, including pregabalin and gabapentin, drugs primarily used for epilepsy but also effective for nerve pain. However, pregabalin has contraindications for individuals with heart, liver, or kidney disease and is often not prescribed to those over 65. Gabapentin, while less common in side effects, can be addictive, requiring gradual dose reduction for discontinuation. Topical treatments like capsicum cream, derived from chili peppers, offer some relief for muscle and joint pain. Powerful opioid painkillers, often thought to be effective for chronic pain, are generally considered ineffective for long-term pain management and carry a high risk of addiction, leading the NHS to largely avoid prescribing them for such conditions.
The personal impact of these medications is profound. Ennals describes how nortriptyline, costing approximately 10p per pill, significantly reduced his pain by 30-40%, allowing him to resume exercise and regain a level of physical health he believed was lost. He contrasts this with the £750 per dose cost of his arthritis injection, suggesting the tricyclic has been more impactful for his overall well-being.
While acknowledging that reducing reliance on pharmaceuticals is generally advisable, the immediate consequences of stopping nortriptyline, including the potential return of severe pain and its impact on his mental and physical health, weigh heavily. For now, Ennals intends to continue his medication, recognizing the tangible benefits it provides while remaining aware of the theoretical long-term risks. The decision highlights the complex challenge faced by millions of patients who must balance immediate pain relief and quality of life against potential future health complications.